复锐医疗科技(01696.HK) 公布,由上海复星医药产业发展再授权产品注射用A型肉毒毒素(中国境内商标为达希斐),用于暂时性改善成人因皱眉肌和降眉间肌活动,引起的中度至重度眉间纹的药品注册申请,于近日收到国家药品监督管理局的批准。据悉,复锐医疗科技全资附属公司于2022年12月,获复星医药产业再授权关于该产品在中国内地、香港及澳门,及美容适应症使用、进口、销售及其他商业化的权利许可,原授权方美国...
Source Link复锐医疗科技(01696.HK) 公布,由上海复星医药产业发展再授权产品注射用A型肉毒毒素(中国境内商标为达希斐),用于暂时性改善成人因皱眉肌和降眉间肌活动,引起的中度至重度眉间纹的药品注册申请,于近日收到国家药品监督管理局的批准。据悉,复锐医疗科技全资附属公司于2022年12月,获复星医药产业再授权关于该产品在中国内地、香港及澳门,及美容适应症使用、进口、销售及其他商业化的权利许可,原授权方美国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.